What is Chardan Capital’s Forecast for DRUG FY2025 Earnings?

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – Chardan Capital upped their FY2025 earnings estimates for Bright Minds Biosciences in a research report issued on Wednesday, May 21st. Chardan Capital analyst R. Li now forecasts that the company will post earnings of ($1.23) per share for the year, up from their prior forecast of ($1.25). Chardan Capital has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($1.24) per share.

DRUG has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $85.00 target price on shares of Bright Minds Biosciences in a research report on Wednesday, February 19th. Cowen began coverage on shares of Bright Minds Biosciences in a report on Tuesday, May 13th. They issued a “buy” rating on the stock. TD Cowen began coverage on shares of Bright Minds Biosciences in a report on Tuesday, May 13th. They issued a “buy” rating on the stock. Wall Street Zen lowered shares of Bright Minds Biosciences from a “hold” rating to a “sell” rating in a report on Thursday. Finally, Cantor Fitzgerald raised shares of Bright Minds Biosciences to a “strong-buy” rating in a report on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Bright Minds Biosciences presently has an average rating of “Buy” and a consensus price target of $83.25.

Bright Minds Biosciences Trading Down 4.0%

Shares of DRUG stock opened at $29.01 on Monday. Bright Minds Biosciences has a 1 year low of $0.93 and a 1 year high of $79.02. The firm’s fifty day simple moving average is $32.34 and its 200 day simple moving average is $35.98. The firm has a market capitalization of $204.35 million, a P/E ratio of -170.64 and a beta of -5.32.

Bright Minds Biosciences (NASDAQ:DRUG) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.10.

Institutional Investors Weigh In On Bright Minds Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in DRUG. Bank of America Corp DE acquired a new stake in shares of Bright Minds Biosciences in the 4th quarter valued at $173,000. Jane Street Group LLC acquired a new stake in shares of Bright Minds Biosciences in the 4th quarter valued at $238,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Bright Minds Biosciences in the 1st quarter valued at $505,000. Atika Capital Management LLC acquired a new stake in shares of Bright Minds Biosciences in the 4th quarter valued at $540,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Bright Minds Biosciences in the 1st quarter valued at $802,000. Institutional investors and hedge funds own 40.52% of the company’s stock.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.